Stock comparison
LeMaitre Vascular
Sanofi
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
SNY
Sanofi
Market cap
$106.67B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | SNY | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 61C | LMAT |
| Benjamin Graham | 89A | 40D | LMAT |
| Philip Fisher | 81C | 53C | LMAT |
| Peter Lynch | 67B | 39D | LMAT |
| Joel Greenblatt | 56D | 39D | LMAT |
| Charlie Munger | 68D | 48D | LMAT |
| Terry Smith | 69D | 49D | LMAT |
Side-by-side metrics
| Metric | LMAT | SNY |
|---|---|---|
| Market cap | $2.23B | $106.67B |
| P/E (TTM) | 37.1x | 8.6x |
| EV/EBIT | 36.6x | 10.8x |
| ROIC (TTM) | 9.43% | 11.66% |
| Gross margin | 72.39% | 71.62% |
| Net margin | 24.35% | 17.59% |
| Revenue CAGR 5y | 12.75% | 4.5% |
| EPS CAGR 5y | 19.04% | 6.47% |
| Debt / Equity | 0.5x | 0.3x |
| Dividend yield | 0.84% | 5.57% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs 6.47%+66%
- Revenue CAGR 5y12.75%vs 4.5%+65%
- Net margin24.35%vs 17.59%+28%
SNY leads on
- Market cap$106.67Bvs $2.23B+98%
- Dividend yield5.57%vs 0.84%+85%
- P/E (TTM)8.6xvs 37.1x+77%
- EV/EBIT10.8xvs 36.6x+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.